Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
LOS ANGELES & MELBOURNE, Australia--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing...
Study Analysis Identifies Potential Biomarkers of VELCADE (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma
-- Data suggest possibility of more targeted approach to treatment with VELCADE--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE® (bortezomib) in patients with relapsed/refractory...
SAN ANTONIO (July 28, 2010) — Researchers at The University of Texas Health Science Center San Antonio have found a gene that, when mutated, causes one type of adrenal cancer.
The adrenal glands, one located above each kidney, release dozens of hormones that regulate the body’s response to stress. Adrenaline, for example, regulates heart rate, blood pressure, sweating and other physiological responses. The adrenal glands also maintain proper...
Extra Government money has been pledged to enable cancer patients to access more expensive drugs.
The additional £50 million is in line with a promised fund for April 2011, and will now be available from October this year, Health Secretary Andrew Lansley said.
The acceleration of the money comes after international drug usage was reviewed by the Department of Health cancer director Mike Richards. He found that the UK's willingness to...
Less expensive versions of the Gemzar cancer drug, manufactured by Eli Lilly, may appear in the US in November.
The firm has tried to argue that its product should be protected from generic copying because a patent of the method by which the drug is administered lasts until the middle of 2013.
But a US federal appeal court ruled Eli Lilly's claim invalid.
The drug's basic chemical patent lapses in November, which means the...
